BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 21239864)

  • 21. CNS relapses of acute promyelocytic leukemia after all-trans retinoic acid.
    Burry LD; Seki JT
    Ann Pharmacother; 2002 Dec; 36(12):1900-6. PubMed ID: 12452754
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups.
    Mandelli F; Diverio D; Avvisati G; Luciano A; Barbui T; Bernasconi C; Broccia G; Cerri R; Falda M; Fioritoni G; Leoni F; Liso V; Petti MC; Rodeghiero F; Saglio G; Vegna ML; Visani G; Jehn U; Willemze R; Muus P; Pelicci PG; Biondi A; Lo Coco F
    Blood; 1997 Aug; 90(3):1014-21. PubMed ID: 9242531
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Eradication of acute promyelocytic leukemia-initiating cells by PML/RARA-targeting.
    Nasr R; de Thé H
    Int J Hematol; 2010 Jun; 91(5):742-7. PubMed ID: 20455087
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinico-biological features and prognostic significance of PML/RARalpha isoforms in adult patients with acute promyelocytic leukemia treated with all trans retinoic acid (ATRA) and chemotherapy.
    Gupta V; Yib QL; Brandwein J; Chun K; Lipton JH; Messner H; Schuh AC; Wells RA; Minden MD; Kamel-Reidc S
    Leuk Lymphoma; 2004 Mar; 45(3):469-80. PubMed ID: 15160908
    [TBL] [Abstract][Full Text] [Related]  

  • 25. AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study.
    Avvisati G; Lo Coco F; Diverio D; Falda M; Ferrara F; Lazzarino M; Russo D; Petti MC; Mandelli F
    Blood; 1996 Aug; 88(4):1390-8. PubMed ID: 8695858
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PML/RARα-Regulated miR-181a/b Cluster Targets the Tumor Suppressor RASSF1A in Acute Promyelocytic Leukemia.
    Bräuer-Hartmann D; Hartmann JU; Wurm AA; Gerloff D; Katzerke C; Verga Falzacappa MV; Pelicci PG; Müller-Tidow C; Tenen DG; Niederwieser D; Behre G
    Cancer Res; 2015 Aug; 75(16):3411-24. PubMed ID: 26041820
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acute promyelocytic leukemia M3: cytomorphologic, immunophenotypic, cytogenetic, and molecular variants.
    Sucić M; Zadro R; Burazer B; Labar B; Nemet D; Mrsić M; Aurer I; Mrsić S; Hitrec V; Boban D; Marković-Glamocak M; Batinić D; Uzarević B; Stavljenić-Rukavina A
    J Hematother Stem Cell Res; 2002 Dec; 11(6):941-50. PubMed ID: 12590709
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Caspases mediate retinoic acid-induced degradation of the acute promyelocytic leukemia PML/RARalpha fusion protein.
    Nervi C; Ferrara FF; Fanelli M; Rippo MR; Tomassini B; Ferrucci PF; Ruthardt M; Gelmetti V; Gambacorti-Passerini C; Diverio D; Grignani F; Pelicci PG; Testi R
    Blood; 1998 Oct; 92(7):2244-51. PubMed ID: 9746761
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML/RAR alpha fusion gene.
    Meloni G; Diverio D; Vignetti M; Avvisati G; Capria S; Petti MC; Mandelli F; Lo Coco F
    Blood; 1997 Aug; 90(3):1321-5. PubMed ID: 9242568
    [TBL] [Abstract][Full Text] [Related]  

  • 30. C-fms expression correlates with monocytic differentiation in PML-RAR alpha+ acute promyelocytic leukemia.
    Riccioni R; Saulle E; Militi S; Sposi NM; Gualtiero M; Mauro N; Mancini M; Diverio D; Lo Coco F; Peschle C; Testa U
    Leukemia; 2003 Jan; 17(1):98-113. PubMed ID: 12529666
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PML nuclear body disruption impairs DNA double-strand break sensing and repair in APL.
    di Masi A; Cilli D; Berardinelli F; Talarico A; Pallavicini I; Pennisi R; Leone S; Antoccia A; Noguera NI; Lo-Coco F; Ascenzi P; Minucci S; Nervi C
    Cell Death Dis; 2016 Jul; 7(7):e2308. PubMed ID: 27468685
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The PML-RARalpha fusion protein and targeted therapy for acute promyelocytic leukemia.
    Jing Y
    Leuk Lymphoma; 2004 Apr; 45(4):639-48. PubMed ID: 15160934
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Study on conversion of RARalpha/PML fusion gene in acute promyelocytic leukemia].
    Liu Y; Le X; Xue W; Yu X; Guo N; Lu D; Chen S
    Zhonghua Xue Ye Xue Za Zhi; 1997 Aug; 18(8):400-2. PubMed ID: 15625843
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting of PML/RARalpha is lethal to retinoic acid-resistant promyelocytic leukemia cells.
    Nason-Burchenal K; Allopenna J; Bègue A; Stéhelin D; Dmitrovsky E; Martin P
    Blood; 1998 Sep; 92(5):1758-67. PubMed ID: 9716606
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early detection of meningeal localization in acute promyelocytic leukaemia patients with high presenting leucocyte count.
    Breccia M; Carmosino I; Diverio D; De Santis S; De Propris MS; Romano A; Petti MC; Mandelli F; Lo-Coco F
    Br J Haematol; 2003 Jan; 120(2):266-70. PubMed ID: 12542484
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of PML-RARα is up-regulated during ATRA and arsenics combined induction without influence on long-term prognosis of acute promyelocytic leukemia.
    Zhu HH; Qin YZ; Lai YY; Shi HX; Liu YR; Jiang B; Huang XJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Aug; 21(4):872-8. PubMed ID: 23998577
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The genetics and clinical characteristics of children morphologically diagnosed as acute promyelocytic leukemia.
    Zhao J; Liang JW; Xue HL; Shen SH; Chen J; Tang YJ; Yu LS; Liang HH; Gu LJ; Tang JY; Li BS
    Leukemia; 2019 Jun; 33(6):1387-1399. PubMed ID: 30575821
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of PML-RAR alpha fusion mRNA type with pretreatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia: an intergroup molecular study.
    Gallagher RE; Willman CL; Slack JL; Andersen JW; Li YP; Viswanatha D; Bloomfield CD; Appelbaum FR; Schiffer CA; Tallman MS; Wiernik PH
    Blood; 1997 Aug; 90(4):1656-63. PubMed ID: 9269786
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transcription therapy for acute promyelocytic leukaemia.
    Douer D
    Expert Opin Investig Drugs; 2000 Feb; 9(2):329-46. PubMed ID: 11060680
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Missense mutations in the PML/RARalpha ligand binding domain in ATRA-resistant As(2)O(3) sensitive relapsed acute promyelocytic leukemia.
    Marasca R; Zucchini P; Galimberti S; Leonardi G; Vaccari P; Donelli A; Luppi M; Petrini M; Torelli G
    Haematologica; 1999 Nov; 84(11):963-8. PubMed ID: 10553155
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.